Intralesional Triamcinolone for Flares of Hidradenitis Suppurativa: A Case Series

The study evaluated the effectiveness of intralesional triamcinolone (10 mg/mL) for managing acute flares in hidradenitis suppurativa (HS) through a prospective case series. Significant reductions in physician-assessed erythema, edema, suppuration, and lesion size were observed (all P < .0001). Patient-reported pain scores also significantly decreased after 1 day (from 5.5 to 2.3, P < .005) and from day 1 to day 2 (from 2.3 to 1.4, P < .002). Despite the small study size, open single-arm design, and short follow-up time, both physicians and patients perceived intralesional corticosteroid injections as beneficial for reducing pain and inflammation in HS flares.